gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Fms-related tyrosine kinase 1

Flt-1, Vascular Endothelial Growth Factor Receptor-1, VEGFR-1, vascular endothelial growth factor receptor
This gene encodes a member of the vascular endothelial growth factor receptor (VEGFR) family. VEGFR family members are receptor tyrosine kinases (RTKs) which contain an extracellular ligand-binding region with seven immunoglobulin (Ig)-like domains, a transmembrane segment, and a tyrosine kinase (TK) domain within the cytoplasmic domain. This protein binds to VEGFR-A, VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis. Expression of this receptor is found in vascular endothelial cells, placental trophoblast cells and peripheral blood monocytes. Multiple transcript variants encoding different isoforms have been found for this gene. Isoforms include a full-length transmembrane receptor isoform and shortened, soluble isoforms. The soluble isoforms are associated with the onset of pre-eclampsia.[provided by RefSeq, May 2009] (from NCBI)
Top mentioned proteins: KDR, vascular endothelial growth factor, HAD, CAN, V1a
Papers using Flt-1 antibodies
Smoking is associated with depletion of circulating endothelial progenitor cells and elevated pulmonary artery systolic pressure in patients with coronary artery disease.
Conklin Daniel J. et al., In Environmental Health Perspectives, 2009
... and immunolabeled with PE-anti-Sca-1 (phycoerythrin-conjugated stem cell antigen-1) and APC-anti-Flk-1 [allophycocyanin-conjugated fetal liver kinase-1 (VEGFR2, vascular endothelial growth factor receptor 2), 1 µg; BD BioSciences, San Jose, CA] ...
HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells
Xu Qingbo et al., In The Journal of Cell Biology, 2005
... Antibodies against CD31 (rat), Flk-1, and Flt-1 were purchased from Abcam; antibodies against CD106 (rat) ...
Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly
Ganjoo Kristen et al., In Case Reports in Oncology, 2002
... sc-1881), goat anti-human VEGFD (N-19) polyclonal antibody (Santa Cruz Biotechnology, Inc.; unit # sc-7603), mouse anti-human VEGFR1 monoclonal antibody (Santa Cruz Biotechnology, Inc.; unit # sc-65442), rabbit ...
Papers on Flt-1
Fully quantified spectral imaging reveals in vivo membrane protein interactions.
Hristova et al., Baltimore, United States. In Integr Biol (camb), Feb 2016
We use the FSI method to study the lateral interactions of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), a member of the receptor tyrosine kinase (RTK) superfamily, in plasma membranes, in vivo.
A novel bispecific diabody targeting both vascular endothelial growth factor receptor 2 and epidermal growth factor receptor for enhanced anti-tumor activity.
Zhang et al., Nanjing, China. In Biotechnol Prog, Feb 2016
UNASSIGNED: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2) are receptor tyrosine kinases known to play critical roles in the development and progression of tumors.
Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis.
Ding et al., New York City, United States. In Nat Med, Feb 2016
Whereas the chemokine receptor CXCR7, expressed on PCECs, acts to prevent epithelial damage and ameliorate fibrosis after a single round of treatment with bleomycin or hydrochloric acid, repeated injury leads to suppression of CXCR7 expression and recruitment of vascular endothelial growth factor receptor 1 (VEGFR1)-expressing perivascular macrophages.
Lenvatinib: Role in thyroid cancer and other solid tumors.
Habra et al., Houston, United States. In Cancer Treat Rev, Jan 2016
Lenvatinib targets vascular endothelial growth factor receptors 1-3 (VEGFR1-3), fibroblast growth factor receptors 1-4 (FGFR-1-4), RET, c-kit, and platelet-derived growth factor receptor α (PDGFRα).
Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Agarwal et al., Duarte, United States. In Clin Genitourin Cancer, Jan 2016
BACKGROUND: Everolimus is an approved agent for use after disease progression with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma.
Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
Garrido-Laguna et al., Salt Lake City, United States. In Onco Targets Ther, Dec 2015
Targeted therapies against EGFR, vascular endothelial growth factor, and vascular endothelial growth factor receptor have expanded treatment options for patients with metastatic colorectal cancer (mCRC).
Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma.
Awut et al., Ürümqi, China. In Oncol Lett, Dec 2015
UNASSIGNED: The present study aimed to understand the expression characteristics of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR-2) in individuals of Uygur, Han and Kazak ethnicity with esophageal carcinoma in Xinjiang (China) and their interrelation analysis, and to investigate the expression differences in these genes between esophageal carcinoma and pericarcinoma tissue samples, and between the three ethnic groups.
Maggot debridement therapy promotes diabetic foot wound healing by up-regulating endothelial cell activity.
Wang et al., Nanjing, China. In J Diabetes Complications, Dec 2015
In vitro, ES increased HUVEC proliferation, improved tube formation, and increased expression of vascular endothelial growth factor receptor 2 in a dose dependent manner.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
METEOR Investigators et al., Villejuif, France. In N Engl J Med, Dec 2015
BACKGROUND: Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs.
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
Paul et al., Manchester, United Kingdom. In Lancet Oncol, Nov 2015
Cediranib is a potent tyrosine kinase inhibitor of VEGFR1, 2, and 3.
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
Ravaud et al., Bordeaux, France. In J Clin Oncol, Nov 2015
This phase II study was conducted to evaluate trebananib plus sunitinib, a vascular endothelial growth factor receptor inhibitor, in patients with metastatic clear cell renal cell carcinoma.
Human Papillomavirus-Negative Pharyngeal Cancer.
Harrington et al., London, United Kingdom. In J Clin Oncol, Nov 2015
In this review, we discuss the evidence for the current treatment of locally advanced human papillomavirus-negative HNSCC, as well as investigational therapies, such as hypoxia modification, molecular targeting of epidermal growth factor receptor family, vascular endothelial growth factor receptor or DNA damage response proteins in combination with radiation therapy.
VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature.
Săftoiu et al., In Rom J Intern Med, Jul 2015
VEGF protein family currently comprises several members: VEGF (or VEGF-A), VEGF-B, VEGF-C and VEGF-D, VEGF-F, placental growth factor (PlGF), and their receptors VEGFR-1, VEGFR-2 and VEGFR-3.
Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Antonelli et al., Pisa, Italy. In Front Endocrinol (lausanne), 2014
Rearranged during transfection (RET)/PTC gene rearrangements, RET mutations, BRAF mutations, RAS mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways determinant in the development of TC.
Overview of fundamental study of pazopanib in cancer.
Zhou et al., Tianjin, China. In Thorac Cancer, 2014
Through the exploration of inhibitors of vascular endothelial growth factor receptor (VEGFR)-2, deemed as the major angiogenesis pathway, pazopanib was found as a small molecular pan-VEGFR and pan-platelet-derived growth factor receptor (PDGFR) inhibitor, with suitable pharmacodynamic and pharmacokinetic parameters to be an oral drug.
Vascular endothelial growth factor-induced osteopontin expression mediates vascular inflammation and neointima formation via Flt-1 in adventitial fibroblasts.
Gao et al., Shanghai, China. In Arterioscler Thromb Vasc Biol, 2012
VEGF/Flt-1 signaling plays a significant role in vascular inflammation and neointima formation by regulating osteopontin expression in vascular adevntitial fibroblasts.
Elevated vascular endothelial growth factor receptor-2 abundance contributes to increased angiogenesis in vascular endothelial growth factor receptor-1-deficient mice.
Fong et al., Farmington, United States. In Circulation, 2012
In a postinfarct ischemic cardiomyopathy model, VEGFR-1 deficiency supports robust angiogenesis and protects against myocardial infarction.
ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1.
Yaniv et al., Israel. In Nat Med, 2012
identified downregulation of vascular endothelial growth factor receptor 1 (VEGFR1), which acts as a decoy receptor for VEGF, as a key mediator of the endothelial response to lipoproteins
Changes in expression of vascular endothelial growth factor and its receptors in the aging mouse cochlea, part 1: the normal-hearing mouse.
Lin et al., Toronto, Canada. In J Otolaryngol Head Neck Surg, 2012
Stria vascularis vasculature and expression of VEGF, Flt-1, and Flk-1 do not change with age, and there appears to be no apical to basal differential expression.
The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis.
Ahmed et al., Edinburgh, United Kingdom. In Nat Commun, 2011
The findings indicate that VEGFR-1 subunits modulate VEGF activity predominantly by forming heterodimer receptors with VEGFR-2 subunits and such heterodimers regulate endothelial cell homeostasis.
share on facebooktweetadd +1mail to friends